talquetamab
janssen
['mmsm', 'monumental-1', 'multiple myeloma', 'talquetamab']
new findings from the phase 1/2 monumental-1 trial showed talquetamab induced an overall response rate exceeding 70% in a population of patients with heavily pre-treated relapsed/refractory multiple myeloma. #mmsm #ash22 | 
Oncology news and insights from leading researchers and cancer centers.